DermTech (NASDAQ: DMTK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
DermTech Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
DermTech Company Info
DermTech's Pigmented Lesion Assay (PLA) offers a noninvasive approach that greatly improves accuracy in detecting early-stage melanoma.
News & Analysis
This beaten-down healthcare stock has started the new year off with a bang.
These two stocks have sky-high potential.
It may depend on the underlying premise of what the company is all about.
Skin-cancer detection could lead to big returns for this stock.
Nothing major changed for the skin genomics company in Q3.
One Motley Fool contributor is looking forward to the quarterly updates from these healthcare stocks.
These three facts can help you determine whether you want in on this fast-growing company.
These stocks have what it takes to deliver 100% returns in five years or less.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/27/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.